Do analysts rate SCNI or BCAB?

BioAtla has a consensus target price of $200.00, indicating a potential upside of 13,413.51%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SCNI or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A BioAtla N/A N/A -289.67%

Do analysts prefer SCNI or MBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNI or MBIO more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Mustang Bio N/A -34.23% -17.55%

Do analysts prefer HCWB or SCNI?

HCW Biologics currently has a consensus price target of $30.00, suggesting a potential upside of 1,454.40%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor HCWB or SCNI?

In the previous week, HCW Biologics had 3 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 8 mentions for HCW Biologics and 5 mentions for Scinai Immunotherapeutics. HCW Biologics' average media sentiment score of 0.69 beat Scinai Immunotherapeutics' score of 0.35 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scinai Immunotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BRTX or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate TCRT or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TCRT or SCNI more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -232.60% -158.99% Scinai Immunotherapeutics N/A N/A N/A

Does the media favor TCRT or SCNI?

In the previous week, Scinai Immunotherapeutics had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.46 beat Scinai Immunotherapeutics' score of 0.35 indicating that Alaunos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alaunos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scinai Immunotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Scinai Immunotherapeutics (SCNI) Competitors

$1.55 -0.31 (-16.67%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.57 +0.02 (+1.35%)

As of 09/25/2026 07:56 PM Eastern

Compare

SCNI vs. BCAB, MBIO, HCWB, BRTX, and TCRT

Should you buy Scinai Immunotherapeutics stock or one of its competitors? Scinai Immunotherapeutics's main competitors and comparable companies include BioAtla (BCAB), Mustang Bio (MBIO), HCW Biologics (HCWB), Biorestorative Therapies (BRTX), and Alaunos Therapeutics (TCRT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scinai Immunotherapeutics compare to BioAtla?

Scinai Immunotherapeutics (NASDAQ:SCNI) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Scinai Immunotherapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Scinai Immunotherapeutics has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.84	-$8.31M	-$95.34	N/A
BioAtla	$8.50M	0.29	-$59.61M	-$25.45	N/A

BioAtla has a consensus target price of $200.00, indicating a potential upside of 13,413.51%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Scinai Immunotherapeutics had 5 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 0 mentions for BioAtla. Scinai Immunotherapeutics' average media sentiment score of 0.35 beat BioAtla's score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
BioAtla	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
BioAtla	N/A	N/A	-289.67%

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 9.3% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Scinai Immunotherapeutics beats BioAtla on 8 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Mustang Bio?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Mustang Bio (NASDAQ:MBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 9.9% of Mustang Bio shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 4.0% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mustang Bio has lower revenue, but higher earnings than Scinai Immunotherapeutics. Mustang Bio is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.84	-$8.31M	-$95.34	N/A
Mustang Bio	N/A	N/A	-$1.92M	-$0.45	N/A

In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than Mustang Bio. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.79 beat Scinai Immunotherapeutics' score of 0.35 indicating that Mustang Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Mustang Bio	Very Positive

Scinai Immunotherapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Mustang Bio	N/A	-34.23%	-17.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Scinai Immunotherapeutics beats Mustang Bio on 8 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

HCW Biologics has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

In the previous week, HCW Biologics had 3 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 8 mentions for HCW Biologics and 5 mentions for Scinai Immunotherapeutics. HCW Biologics' average media sentiment score of 0.69 beat Scinai Immunotherapeutics' score of 0.35 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scinai Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HCW Biologics currently has a consensus price target of $30.00, suggesting a potential upside of 1,454.40%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities analysts clearly believe HCW Biologics is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HCW Biologics has higher revenue and earnings than Scinai Immunotherapeutics. HCW Biologics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.72M	0.53	-$7.96M	-$27.60	N/A
Scinai Immunotherapeutics	$1.31M	0.84	-$8.31M	-$95.34	N/A

Scinai Immunotherapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Scinai Immunotherapeutics' return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Scinai Immunotherapeutics	N/A	N/A	N/A

Summary

HCW Biologics beats Scinai Immunotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scinai Immunotherapeutics has higher revenue and earnings than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	9.78	-$14.24M	-$21.40	N/A
Scinai Immunotherapeutics	$1.31M	0.84	-$8.31M	-$95.34	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Scinai Immunotherapeutics had 3 more articles in the media than Biorestorative Therapies. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.39 beat Scinai Immunotherapeutics' score of 0.35 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Positive
Scinai Immunotherapeutics	Neutral

Biorestorative Therapies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Scinai Immunotherapeutics has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Scinai Immunotherapeutics' return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Scinai Immunotherapeutics	N/A	N/A	N/A

Summary

Scinai Immunotherapeutics beats Biorestorative Therapies on 9 of the 13 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Alaunos Therapeutics has a beta of -0.97, indicating that its stock price is 197% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-232.60%	-158.99%
Scinai Immunotherapeutics	N/A	N/A	N/A

Alaunos Therapeutics has higher earnings, but lower revenue than Scinai Immunotherapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$3K	922.87	-$4.18M	-$1.91	N/A
Scinai Immunotherapeutics	$1.31M	0.84	-$8.31M	-$95.34	N/A

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Scinai Immunotherapeutics had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.46 beat Scinai Immunotherapeutics' score of 0.35 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alaunos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scinai Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scinai Immunotherapeutics beats Alaunos Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNI vs. The Competition

Export

Metric	Scinai Immunotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.10M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.02	14.15	275.82	25.78
Price / Sales	0.84	1,442.79	650.06	92.83
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	0.20	15.28	10.44	6.30
Net Income	-$8.31M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-0.64%	-2.94%	-1.31%	-0.23%
1 Month Performance	-42.16%	-8.80%	-4.61%	-4.16%
1 Year Performance	-88.26%	28.99%	15.01%	4.58%

Scinai Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNI Scinai Immunotherapeutics	0.4606 of 5 stars	$1.55 -16.7%	N/A	-88.3%	$1.10M	$1.31M	N/A	45	News Coverage Short Interest Increase Gap Down
BCAB BioAtla	1.3825 of 5 stars	$1.90 -20.8%	$200.00 +10,426.3%	-95.6%	$4.00M	$8.50M	N/A	60	Positive News Gap Up
MBIO Mustang Bio	0.8657 of 5 stars	$0.49 -2.0%	N/A	-67.3%	$3.79M	N/A	N/A	100	Positive News Gap Up
HCWB HCW Biologics	3.9333 of 5 stars	$1.95 -3.0%	$30.00 +1,438.5%	-92.1%	$3.58M	$6.72M	N/A	40	News Coverage Short Interest Decrease
BRTX Biorestorative Therapies	1.3079 of 5 stars	$2.65 +3.9%	N/A	-91.1%	$3.52M	$360K	N/A	7	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. BCAB, MBIO, HCWB, BRTX, and TCRT

How does Scinai Immunotherapeutics compare to BioAtla?

Summary

How does Scinai Immunotherapeutics compare to Mustang Bio?

Summary

How does Scinai Immunotherapeutics compare to HCW Biologics?

Summary

How does Scinai Immunotherapeutics compare to Biorestorative Therapies?

Summary

How does Scinai Immunotherapeutics compare to Alaunos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. BCAB, MBIO, HCWB, BRTX, and TCRT

How does Scinai Immunotherapeutics compare to BioAtla?

Which has more risk & volatility, SCNI or BCAB?

Which has better valuation and earnings, SCNI or BCAB?

Do analysts rate SCNI or BCAB?

Does the media favor SCNI or BCAB?

Is SCNI or BCAB more profitable?

Do institutionals & insiders believe in SCNI or BCAB?

Summary

How does Scinai Immunotherapeutics compare to Mustang Bio?

Do institutionals & insiders believe in SCNI or MBIO?

Which has higher valuation and earnings, SCNI or MBIO?

Does the media prefer SCNI or MBIO?

Which has more volatility & risk, SCNI or MBIO?

Is SCNI or MBIO more profitable?

Do analysts prefer SCNI or MBIO?

Summary

How does Scinai Immunotherapeutics compare to HCW Biologics?

Do insiders and institutionals have more ownership in HCWB or SCNI?

Which has more risk & volatility, HCWB or SCNI?

Does the media favor HCWB or SCNI?

Do analysts prefer HCWB or SCNI?

Which has better earnings & valuation, HCWB or SCNI?

Is HCWB or SCNI more profitable?

Summary

How does Scinai Immunotherapeutics compare to Biorestorative Therapies?

Do institutionals and insiders believe in BRTX or SCNI?

Which has higher valuation and earnings, BRTX or SCNI?

Do analysts rate BRTX or SCNI?

Does the media refer more to BRTX or SCNI?

Which has more risk and volatility, BRTX or SCNI?

Is BRTX or SCNI more profitable?

Summary

How does Scinai Immunotherapeutics compare to Alaunos Therapeutics?

Which has more volatility & risk, TCRT or SCNI?

Is TCRT or SCNI more profitable?

Which has higher earnings and valuation, TCRT or SCNI?

Do insiders & institutionals have more ownership in TCRT or SCNI?

Do analysts rate TCRT or SCNI?

Does the media favor TCRT or SCNI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools